Trial Profile
Phase II Pilot Study On The Effect Of Methylphenidate On Cognitive Function Of Patients In Remission Of Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- Acronyms CogMet
- 21 Mar 2023 Status changed from recruiting to discontinued.
- 10 Dec 2021 Planned End Date changed from 1 Dec 2020 to 31 Dec 2022.
- 10 Dec 2021 Planned primary completion date changed from 1 Dec 2020 to 31 Dec 2022.